title: Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
abstract: The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
authors.affiliation: Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
authors.forename: Kara L
authors.initials: KL
authors.lastname: O'Brien
authors.forename: Jinyan
authors.initials: J
authors.lastname: Liu
authors.forename: Sharon L
authors.initials: SL
authors.lastname: King
authors.forename: Ying-Hua
authors.initials: YH
authors.lastname: Sun
authors.forename: Joern E
authors.initials: JE
authors.lastname: Schmitz
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Lifton
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Hutnick
authors.forename: Michael R
authors.initials: MR
authors.lastname: Betts
authors.forename: Sheri A
authors.initials: SA
authors.lastname: Dubey
authors.forename: Jaap
authors.initials: J
authors.lastname: Goudsmit
authors.forename: John W
authors.initials: JW
authors.lastname: Shiver
authors.forename: Michael N
authors.initials: MN
authors.lastname: Robertson
authors.forename: Danilo R
authors.initials: DR
authors.lastname: Casimiro
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000256:Adenoviridae / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D000918:Antibody Specificity / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007371:Interferon-gamma / Q000378:metabolism; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D007371:Interferon-gamma